Indivior Pharmaceuticals, Inc. INDV Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's business segments — D&A?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — D&A of $2M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's business segments — D&A changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's business segments — D&A decreased by 33.3% year-over-year, from $3M to $2M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's business segments — D&A?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's business segments — D&A has grown at a -18.4% compound annual growth rate (CAGR), from $15M to $10M.
- What does business segments — D&A mean?
- This represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the reportable segment. Monitoring this helps investors understand the capital intensity and the ongoing reinvestment requirements of the segment's operations.